Drugs / NK521 Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07657416 | Jun 2026 → Oct 2027 expected | hepatocellular carcinoma, ovarian carcinoma, peritoneal neoplasm | Base Therapeutics (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK521 Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07657416 ↗ |
| Action | Inhibit | “knockout of TIGIT” NCT07657416 ↗ |
| Modality | Cell therapy | “Gene-edited natural killer (NK) cell product” NCT07657416 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT07657416 ↗ |
| Target | TIGIT | “knockout of TIGIT” NCT07657416 ↗ |